London, Ontario — A 52-week randomized, double-blind, placebo-controlled phase 2 trial has found that high-dose ambroxol, a common cough medicine repurposed as a molecular chaperone, is safe and achieves biochemical target engagement in Parkinson disease dementia (PDD), but shows no measurable cognitive benefits compared to placebo.